Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.

Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, Sundar D.

BMC Bioinformatics. 2011 Feb 15;12 Suppl 1:S30. doi: 10.1186/1471-2105-12-S1-S30.

2.

Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.

Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, Sundar D.

Biochem Biophys Res Commun. 2011 Jan 7;404(1):498-503. doi: 10.1016/j.bbrc.2010.12.010. Epub 2010 Dec 6.

PMID:
21144839
3.

Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera's key metabolite withaferin A.

Grover A, Shandilya A, Punetha A, Bisaria VS, Sundar D.

BMC Genomics. 2010 Dec 2;11 Suppl 4:S25. doi: 10.1186/1471-2164-11-S4-S25.

4.

Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.

Grover A, Shandilya A, Bisaria VS, Sundar D.

BMC Genomics. 2010 Dec 2;11 Suppl 4:S15. doi: 10.1186/1471-2164-11-S4-S15.

5.

Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling.

Widodo N, Priyandoko D, Shah N, Wadhwa R, Kaul SC.

PLoS One. 2010 Oct 21;5(10):e13536. doi: 10.1371/journal.pone.0013536.

6.

The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme?

Asteriti IA, Rensen WM, Lindon C, Lavia P, Guarguaglini G.

Biochim Biophys Acta. 2010 Dec;1806(2):230-9. doi: 10.1016/j.bbcan.2010.08.001. Epub 2010 Aug 12. Review.

PMID:
20708655
7.

Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.

Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H, Von Hoff DD.

Clin Cancer Res. 2009 Nov 1;15(21):6519-28. doi: 10.1158/1078-0432.CCR-09-0077. Epub 2009 Oct 27.

8.

TPX2 in malignantly transformed human bronchial epithelial cells by anti-benzo[a]pyrene-7,8-diol-9,10-epoxide.

Zhang L, Huang H, Deng L, Chu M, Xu L, Fu J, Zhu Y, Zhang X, Liu S, Zhou Z, Wang Y.

Toxicology. 2008 Oct 30;252(1-3):49-55. doi: 10.1016/j.tox.2008.07.059. Epub 2008 Aug 3.

PMID:
18723071
9.

Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.

Zhao B, Smallwood A, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Lai Z.

Protein Sci. 2008 Oct;17(10):1791-7. doi: 10.1110/ps.036590.108. Epub 2008 Jul 28.

10.

Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression.

Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Murty VV.

Genes Chromosomes Cancer. 2008 Sep;47(9):755-65. doi: 10.1002/gcc.20577.

PMID:
18506748
11.

Selective killing of cancer cells by leaf extract of Ashwagandha: components, activity and pathway analyses.

Widodo N, Takagi Y, Shrestha BG, Ishii T, Kaul SC, Wadhwa R.

Cancer Lett. 2008 Apr 8;262(1):37-47. doi: 10.1016/j.canlet.2007.11.037. Epub 2008 Jan 10.

PMID:
18191020
12.

ParDOCK: an all atom energy based Monte Carlo docking protocol for protein-ligand complexes.

Gupta A, Gandhimathi A, Sharma P, Jayaram B.

Protein Pept Lett. 2007;14(7):632-46.

PMID:
17897088
13.

Binding of TPX2 to Aurora A alters substrate and inhibitor interactions.

Anderson K, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Patrick D, Silva D, Tummino PJ, Copeland RA, Lai Z.

Biochemistry. 2007 Sep 11;46(36):10287-95. Epub 2007 Aug 18.

PMID:
17705509
14.

The role of Aurora-A inhibitors in cancer therapy.

Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A.

Ann Oncol. 2007 Jun;18 Suppl 6:vi47-52. Review.

15.

Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.

Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D, Vernetti L, Schurdak M, Wang J, Fesik SW.

Cancer Res. 2007 May 1;67(9):4390-8.

16.

Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect.

Widodo N, Kaur K, Shrestha BG, Takagi Y, Ishii T, Wadhwa R, Kaul SC.

Clin Cancer Res. 2007 Apr 1;13(7):2298-306.

17.
18.

Aurora kinases: shining lights on the therapeutic horizon?

Andrews PD.

Oncogene. 2005 Jul 28;24(32):5005-15. Review.

PMID:
16049526
19.

High-resolution genomic profiles of human lung cancer.

Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA.

Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30. Epub 2005 Jun 27.

20.

Aurora-A over-expression in high-grade PIN lesions and prostate cancer.

Buschhorn HM, Klein RR, Chambers SM, Hardy MC, Green S, Bearss D, Nagle RB.

Prostate. 2005 Sep 1;64(4):341-6.

PMID:
15754349
Items per page

Supplemental Content

Write to the Help Desk